News Sentiment

AUPH sentiment intelligence

Aurinia Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 16.46 Week of 19 Jun 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+4.0% over one week, +8.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Understanding Momentum Shifts in (AUPH)

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 4.0% Price confirming higher
Trend fit Trend active 8.1% over four weeks
Fair value 70.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 10
simplywall.st 8
TradingKey 3
AD HOC NEWS 3
Stock Traders Daily 2
ChartMill 2
Benzinga 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 14
Deals and strategy 5
Analyst action 4
Balance sheet 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (AUPH)

This article analyzes Aurinia Pharmaceuticals Inc (AUPH), indicating a strong overweight bias across all time horizons due to strong sentiment. It identifies a mid-channel oscillation pattern and offers three distinct AI-generated trading strategies with specific entry, target, a

Tone
Positive 75/100
Event
Analyst action
Published
19 Jun 2026 20:08
Source
Stock Traders Daily
Sahm Direct company coverage

How New LUPKYNIS Renal Outcomes Data Could Impact Aurinia Pharmaceuticals (AUPH) Investors

Aurinia Pharmaceuticals recently announced new AURORA 1 Phase 3 analysis at the EULAR 2026 Congress, showing LUPKYNIS significantly reduced renal-related events or death in lupus nephritis patients. This data strengthens the clinical evidence for the drug but does not eliminate r

Tone
Positive 63/100
Event
Market update
Published
19 Jun 2026 04:41
Source
Sahm
TradingKey Direct company coverage

Aurinia Pharmaceuticals Inc (AUPH) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Aurinia Pharmaceuticals Inc's (AUPH) shareholder structure, listing major shareholders and institutional holdings. It highlights top individual shareholders like Tang Capital Management, LLC and BlackRock, along with a classification

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 08:38
Source
TradingKey
TradingKey Direct company coverage

Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Aurinia Pharmaceuticals Inc (AUPH), detailing regional contributions. It shows that the United States accounts for 93.21% of its revenue, totaling $263.84 million, while Japan contributes 6.79% with $19.21 million. Information on reve

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:10
Source
TradingKey
TradingKey Direct company coverage

Aurinia Pharmaceuticals Inc (AUPH) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aurinia Pharmaceuticals Inc (AUPH) has an earnings forecast score of 7.43, ranking 291 out of 388 in its industry. Analysts have set an average price target of $17.00 for AUPH, with most supporting a "Buy" trend. The company's expected revenue for the next quarter is $79.70 milli

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 18:10
Source
TradingKey
Barron's Direct company coverage

Aurinia Pharmaceuticals and Four More Stocks See Activist Action

This article reports on recent activist actions disclosed to the SEC, specifically focusing on Aurinia Pharmaceuticals and four other companies. The information is derived from 13D filings, which are required when an entity acquires more than 5% ownership in a company's securitie

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 02:40
Source
Barron's
Stock Titan Direct company coverage

Aurinia (AUPH) director Jeffrey Bailey granted 23,931 stock options at $15.67

Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey was granted 23,931 stock options with an exercise price of $15.67 per share. These options are part of his compensation, will vest one year from the grant date, and are set to expire on June 4, 2036. This transaction refl

Tone
Positive 61/100
Event
Market update
Published
08 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Aurinia (NASDAQ: AUPH) director awarded 23,931 stock options expiring 2036

Aurinia Pharmaceuticals director Kathleen Goetz was granted 23,931 Director Stock Options on June 4, 2026, as compensation. These options have an exercise price of $15.67 per share and will expire on June 4, 2036, vesting one year from the grant date. Following this award, her di

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Aurinia Pharmaceuticals (AUPH) director receives 23,931 share option grant

Aurinia Pharmaceuticals Inc. (AUPH) director Tina Susan Nova was granted 23,931 stock options as compensation, which are exercisable at $15.67 per share and will vest one year from the grant date of June 4, 2026. The options are set to expire on June 4, 2036. This transaction is

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Aurinia (NASDAQ: AUPH) director receives grant of 23,931 stock options

Aurinia Pharmaceuticals Inc. director Craig A. Johnson was granted 23,931 stock options as part of his compensation, with an exercise price of $15.67 per share. These options are set to vest one year from the grant date and will expire on June 4, 2036. The Form 4 filing indicates

Tone
Neutral 50/100
Event
Market update
Published
08 Jun 2026 20:10
Source
Stock Titan
The Motley Fool Direct company coverage

Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million

Aurinia Pharmaceuticals' (AUPH) CEO, Kevin Tang, indirectly purchased 814,606 common shares across several transactions between May 29, 2026, and June 2, 2026, totaling approximately $12.5 million. This significant acquisition, representing 6.66% of his total holdings, occurred j

Tone
Positive 70/100
Event
Deals and strategy
Published
07 Jun 2026 13:09
Source
The Motley Fool
Stock Titan Direct company coverage

Insider sales, option exercise at AUPH (NASDAQ: AUPH) reported

A recently filed Form 144 for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) details proposed and recent transactions involving option exercises and sales of common stock. The filing indicates a planned sale of 9,593 shares connected to an option exercise dated June 5, 2026, and als

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:10
Source
Stock Titan
Benzinga Direct company coverage

10 Health Care Stocks Whale Activity In Today's Session

This article identifies significant "whale activity" in the options market for ten healthcare stocks, including Aurinia Pharmaceuticals (AUPH), UnitedHealth Group (UNH), and Eli Lilly and Co (LLY). It details specific bullish or bearish options trades, their expiration dates, str

Tone
Positive 68/100
Event
Market update
Published
05 Jun 2026 17:10
Source
Benzinga
Stock Titan Direct company coverage

Tang group discloses 10% Aurinia (AUPH) stake plus $15 put options

Tang Capital Management and affiliated entities have amended their Schedule 13D filing, revealing a beneficial ownership of 10.0% in Aurinia Pharmaceuticals Inc., totaling 13,044,106 common shares as of June 3, 2026. The filing also discloses that the group holds put option contr

Tone
Neutral 50/100
Event
Deals and strategy
Published
04 Jun 2026 23:08
Source
Stock Titan
Stock Titan Direct company coverage

Strong shareholder support for Aurinia (NASDAQ: AUPH) board, auditor and say-on-pay

Aurinia Pharmaceuticals Inc. shareholders demonstrated strong support for the company's leadership and compensation plan at its 2026 annual general meeting. All five director nominees were elected with significant majorities, ranging from 86.50% to 96.59% of votes. Additionally,

Tone
Positive 67/100
Event
Market update
Published
04 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

AUPH: 25,000-share option exercise filed; Keenan sold 25,000 on 06/02/2026

A Form 144 filing for Aurinia Pharmaceuticals Inc. (AUPH) indicates a 25,000-share option exercise with a proposed sale on June 4, 2026, settled by cash. The filing also notes a previous sale by Gregory Keenan of 25,000 shares on June 2, 2026, for $54,100,000. These transactions

Tone
Neutral 50/100
Event
Balance sheet
Published
04 Jun 2026 20:39
Source
Stock Titan
Seeking Alpha Direct company coverage

Aurinia: Cash-Generating Today, Pipeline-Driven Tomorrow (NASDAQ:AUPH)

Aurinia Pharmaceuticals (AUPH) is poised for profitable growth, buoyed by strong financial results from Lupkynis and strategic pipeline expansion through the Kezar Life Sciences acquisition. The company reported impressive 1Q26 figures, including double-digit revenue and net inco

Tone
Positive 81/100
Event
Deals and strategy
Published
04 Jun 2026 12:39
Source
Seeking Alpha
Moomoo Direct company coverage

Aurinia Pharmaceuticals(AUPH.US) 10% Shareholder Buys US$12.46 Million in Common Stock

A 10% shareholder of Aurinia Pharmaceuticals (AUPH.US) recently purchased 2,367,314 shares of common stock for a total of US$12.46 million. This transaction occurred at an average price of US$5.26 per share. Following this purchase, the shareholder now directly owns 20,449,602 sh

Tone
Positive 72/100
Event
Market update
Published
04 Jun 2026 09:39
Source
Moomoo
Quantisnow Direct company coverage

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

TANG CAPITAL MANAGEMENT, LLC has filed an early warning report concerning Aurinia Pharmaceuticals Inc. (AUPH). Quantisnow, a market data and news platform, provided this update, alerting its Plus members shortly after publication. The platform aggregates real-time information suc

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 23:10
Source
Quantisnow
Benzinga Direct company coverage

Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy

Aurinia Pharmaceuticals' CEO, Kevin Tang, recently made a substantial insider purchase of 814,606 shares, totaling $12.46 million. This transaction signals insider confidence in the company, whose shares saw a 2.47% increase on Wednesday morning. The company demonstrated strong f

Tone
Positive 72/100
Event
Market update
Published
03 Jun 2026 15:10
Source
Benzinga
Stock Titan Direct company coverage

Funds tied to Aurinia Pharmaceuticals (AUPH) add shares, sell put options

Entities linked to Aurinia Pharmaceuticals (AUPH) CEO Kevin Tang significantly increased their stake in the company by purchasing 814,606 common shares at around $15 per share. These funds now indirectly hold 13,044,106 shares. Additionally, Tang-affiliated funds sold 10,000 shor

Tone
Positive 70/100
Event
Deals and strategy
Published
03 Jun 2026 01:33
Source
Stock Titan